Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern

T. Melnikova, Alena Savonenko, Q. Wang, X. Liang, T. Hand, L. Wu, W. E. Kaufmann, A. Vehmas, K. I. Andreasson

Research output: Contribution to journalArticle

Abstract

Administration of non-steroidal anti-inflammatory agents reduces the risk of developing Alzheimer's disease in normal aging populations, an effect that may occur from inhibition of the cyclooxygenases, the rate-limiting enzymes in the formation of prostaglandins. In this study, we investigated whether increased activity of cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase, potentiates disease progression in a transgenic mouse model of Alzheimer's disease. To study the functional effects of COX-2 activity, male and female bigenic mice (amyloid precursor protein with Swedish mutation [APPswe]-presenilin-1 protein with deletion of exon 9 [PS1dE9] and trigenic COX-2/APPswe-PS1dE9) were behaviorally tested ±administration of the selective COX-2 inhibitor celecoxib. Behavioral testing included a three-trial Y maze that measures spatial working and recognition memories and an open field task that tested levels of hyperactivity. Overexpression of COX-2 in APPswe-PS1dE9 mice resulted in specific deficits in spatial working memory in female but not male mice. These sex-specific deficits were abolished by pharmacological inhibition of COX-2 activity. Importantly, COX-2-associated deficits were dependent on co-expression of all three transgenes since COX-2 single transgenic and APPswe-PS1dE9 bigenic mice showed normal memory. Quantification of amyloid plaque load and total Aβ 40 and 42 peptides did not reveal significant differences in trigenic versus bigenic mice treated with either vehicle or celecoxib. Taken together, these data indicate an interaction between the effects of COX-2 and Aβ peptides on cognition that occurs in a sex-specific manner in the absence of significant changes in amyloid burden. These findings suggest that pathological activation of COX-2 may potentiate the toxicity of Aβ peptides, particularly in females, without significantly affecting Aβ accumulation.

Original languageEnglish (US)
Pages (from-to)1149-1162
Number of pages14
JournalNeuroscience
Volume141
Issue number3
DOIs
StatePublished - 2006

Fingerprint

Cyclooxygenase 2
Amyloid
Alzheimer Disease
Presenilin-1
Amyloid beta-Protein Precursor
Celecoxib
Exons
Mutation
Prostaglandin-Endoperoxide Synthases
Short-Term Memory
Peptides
Proteins
Cyclooxygenase 2 Inhibitors
Amyloid Plaques
Non-Steroidal Anti-Inflammatory Agents
Transgenes
Cognition
Transgenic Mice
Prostaglandins
Disease Progression

Keywords

  • APPswe-PS1dE9 mice
  • celecoxib
  • recognition memory
  • sex differences
  • spatial working memory
  • three-trial Y maze

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. / Melnikova, T.; Savonenko, Alena; Wang, Q.; Liang, X.; Hand, T.; Wu, L.; Kaufmann, W. E.; Vehmas, A.; Andreasson, K. I.

In: Neuroscience, Vol. 141, No. 3, 2006, p. 1149-1162.

Research output: Contribution to journalArticle

Melnikova, T. ; Savonenko, Alena ; Wang, Q. ; Liang, X. ; Hand, T. ; Wu, L. ; Kaufmann, W. E. ; Vehmas, A. ; Andreasson, K. I. / Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. In: Neuroscience. 2006 ; Vol. 141, No. 3. pp. 1149-1162.
@article{ca5efc1c170e4a56bce0c34850ff18c2,
title = "Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern",
abstract = "Administration of non-steroidal anti-inflammatory agents reduces the risk of developing Alzheimer's disease in normal aging populations, an effect that may occur from inhibition of the cyclooxygenases, the rate-limiting enzymes in the formation of prostaglandins. In this study, we investigated whether increased activity of cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase, potentiates disease progression in a transgenic mouse model of Alzheimer's disease. To study the functional effects of COX-2 activity, male and female bigenic mice (amyloid precursor protein with Swedish mutation [APPswe]-presenilin-1 protein with deletion of exon 9 [PS1dE9] and trigenic COX-2/APPswe-PS1dE9) were behaviorally tested ±administration of the selective COX-2 inhibitor celecoxib. Behavioral testing included a three-trial Y maze that measures spatial working and recognition memories and an open field task that tested levels of hyperactivity. Overexpression of COX-2 in APPswe-PS1dE9 mice resulted in specific deficits in spatial working memory in female but not male mice. These sex-specific deficits were abolished by pharmacological inhibition of COX-2 activity. Importantly, COX-2-associated deficits were dependent on co-expression of all three transgenes since COX-2 single transgenic and APPswe-PS1dE9 bigenic mice showed normal memory. Quantification of amyloid plaque load and total Aβ 40 and 42 peptides did not reveal significant differences in trigenic versus bigenic mice treated with either vehicle or celecoxib. Taken together, these data indicate an interaction between the effects of COX-2 and Aβ peptides on cognition that occurs in a sex-specific manner in the absence of significant changes in amyloid burden. These findings suggest that pathological activation of COX-2 may potentiate the toxicity of Aβ peptides, particularly in females, without significantly affecting Aβ accumulation.",
keywords = "APPswe-PS1dE9 mice, celecoxib, recognition memory, sex differences, spatial working memory, three-trial Y maze",
author = "T. Melnikova and Alena Savonenko and Q. Wang and X. Liang and T. Hand and L. Wu and Kaufmann, {W. E.} and A. Vehmas and Andreasson, {K. I.}",
year = "2006",
doi = "10.1016/j.neuroscience.2006.05.001",
language = "English (US)",
volume = "141",
pages = "1149--1162",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern

AU - Melnikova, T.

AU - Savonenko, Alena

AU - Wang, Q.

AU - Liang, X.

AU - Hand, T.

AU - Wu, L.

AU - Kaufmann, W. E.

AU - Vehmas, A.

AU - Andreasson, K. I.

PY - 2006

Y1 - 2006

N2 - Administration of non-steroidal anti-inflammatory agents reduces the risk of developing Alzheimer's disease in normal aging populations, an effect that may occur from inhibition of the cyclooxygenases, the rate-limiting enzymes in the formation of prostaglandins. In this study, we investigated whether increased activity of cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase, potentiates disease progression in a transgenic mouse model of Alzheimer's disease. To study the functional effects of COX-2 activity, male and female bigenic mice (amyloid precursor protein with Swedish mutation [APPswe]-presenilin-1 protein with deletion of exon 9 [PS1dE9] and trigenic COX-2/APPswe-PS1dE9) were behaviorally tested ±administration of the selective COX-2 inhibitor celecoxib. Behavioral testing included a three-trial Y maze that measures spatial working and recognition memories and an open field task that tested levels of hyperactivity. Overexpression of COX-2 in APPswe-PS1dE9 mice resulted in specific deficits in spatial working memory in female but not male mice. These sex-specific deficits were abolished by pharmacological inhibition of COX-2 activity. Importantly, COX-2-associated deficits were dependent on co-expression of all three transgenes since COX-2 single transgenic and APPswe-PS1dE9 bigenic mice showed normal memory. Quantification of amyloid plaque load and total Aβ 40 and 42 peptides did not reveal significant differences in trigenic versus bigenic mice treated with either vehicle or celecoxib. Taken together, these data indicate an interaction between the effects of COX-2 and Aβ peptides on cognition that occurs in a sex-specific manner in the absence of significant changes in amyloid burden. These findings suggest that pathological activation of COX-2 may potentiate the toxicity of Aβ peptides, particularly in females, without significantly affecting Aβ accumulation.

AB - Administration of non-steroidal anti-inflammatory agents reduces the risk of developing Alzheimer's disease in normal aging populations, an effect that may occur from inhibition of the cyclooxygenases, the rate-limiting enzymes in the formation of prostaglandins. In this study, we investigated whether increased activity of cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase, potentiates disease progression in a transgenic mouse model of Alzheimer's disease. To study the functional effects of COX-2 activity, male and female bigenic mice (amyloid precursor protein with Swedish mutation [APPswe]-presenilin-1 protein with deletion of exon 9 [PS1dE9] and trigenic COX-2/APPswe-PS1dE9) were behaviorally tested ±administration of the selective COX-2 inhibitor celecoxib. Behavioral testing included a three-trial Y maze that measures spatial working and recognition memories and an open field task that tested levels of hyperactivity. Overexpression of COX-2 in APPswe-PS1dE9 mice resulted in specific deficits in spatial working memory in female but not male mice. These sex-specific deficits were abolished by pharmacological inhibition of COX-2 activity. Importantly, COX-2-associated deficits were dependent on co-expression of all three transgenes since COX-2 single transgenic and APPswe-PS1dE9 bigenic mice showed normal memory. Quantification of amyloid plaque load and total Aβ 40 and 42 peptides did not reveal significant differences in trigenic versus bigenic mice treated with either vehicle or celecoxib. Taken together, these data indicate an interaction between the effects of COX-2 and Aβ peptides on cognition that occurs in a sex-specific manner in the absence of significant changes in amyloid burden. These findings suggest that pathological activation of COX-2 may potentiate the toxicity of Aβ peptides, particularly in females, without significantly affecting Aβ accumulation.

KW - APPswe-PS1dE9 mice

KW - celecoxib

KW - recognition memory

KW - sex differences

KW - spatial working memory

KW - three-trial Y maze

UR - http://www.scopus.com/inward/record.url?scp=33746433950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746433950&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2006.05.001

DO - 10.1016/j.neuroscience.2006.05.001

M3 - Article

C2 - 16753269

AN - SCOPUS:33746433950

VL - 141

SP - 1149

EP - 1162

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 3

ER -